Pharmacoeconomics: theory and practice
№1, 2017, Vol.5

Kulikov A.Y., Snegovoy A.V., Ugrekhelidze D.T. 4962

This article deals with pharmacoeconomic study of erythropoietin use in patients with chemotherapy-induced anemia. Four treatments were evaluated, i.e. Epoetin alfa, Epoetin beta, Epoetin theta and Darbepoetin alfa. The results of pharmacoeconomic analysis show that use of Epoetin theta (Eporatio) is the most cost-effective regimen for anemia treatment in cancer patients. Cost-cutting upon patient’s transition to Eporatio amounts up to 9,129 rubles (transition from Epoetin beta), up to 13,812 rubles (transition from Epoetin alfa) and 165,527 rubles (transition from Darbepoetin alfa). Budget impact analysis demonstrated a possibility of total cost-cutting in the amount of 197,075,449 rubles if purchase share of Eporatio increases to 30% via reducing purchase share of Epoetin alfa by 15%, Epoetin beta by 13% and Darbepoetin alfa by 2%.

Kulikov A.Y., Skripnik A.R. 3819

Iron-deficiency anemia occupies the first place among the most common diseases. Approximately 700 million people worldwide suffer from iron deficiency anemia. In Russia, iron deficiency anemia is diagnosed in 6-30% of the population. The objective of this study was the comparative pharmacoeconomic analysis Cosmofer (Iron III - hydroxide dextran) compared with Venofer (Iron III - hydroxide sucrose complex) in the treatment of iron deficiency anemia for patients with chronic kidney disease. An analysis of the value of the direct costs of patient treatment for 6 months amounted to 17,077 rubles for the treatment of Iron III - hydroxide dextran and 17,792 rubles for the treatment of Iron III - hydroxide sucrose complex. Result of budget impact analysis revealed that the use of the treatment of Iron III - hydroxide dextran as compared with Iron III - hydroxide sucrose complex for one patient, leads to budget savings for 715 rubles. The sensitivity analysis shows that a simultaneous increase the cost of Iron III - hydroxide dextran and decrease the cost of Iron III - hydroxide sucrose complex at 5%, will require additional funding in the amount of 157 ruble.

Arinina E.E., Rashid M.A. 3752

According to the first Global Report of the WHO, diabetes mellitus is an important public health problem, one of four priority noncommunicable diseases (NCDs) targeted for action by world leaders. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades. In the estimation of the WHO, 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. The global prevalence (age-standardized) of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.

Kulikov A.Y., Tishchenko D.G., Yagudina R.I. 3890

Pharmacoeconomic analysis of long-term effects of more widespread use of in vitro fertilization (IVF) in infertility treatment at the regional and federal level from the standpoint of society in the Russian Federation was carried out in this research. The research was performed by means of forecasting of future monetary flows produced by a human born with the aid of in vitro fertilization throughout life. The methods of cost analysis, discounted monetary flows, age shifting and model building were used in the research. The result is that net present value (NPV) of tax payments produced within anticipated life period by the human born with of IVF in the Russian Federation was equal to 822,258 rubles. Return on investments (ROI) was 27%. Net present value (NPV) of GDP produced within the state per one human born with the aid of IVF in the Russian Federation was equal to 34.9 million rubles. Return on investments (ROI) was 985%. Additional carrying out of 24,450 IVF cycles on the basis of OMI CMI (Obligatory Medical Insurance) (the level of 2013) results in increase of total growth of population of the Russian Federation by 22.5%, annual additional carrying out of IVF procedure in the quantity carried out in 2013 will allow to produce additional population growth by 2075 estimated at 319 thousand people in productive age, and 222 thousand people aged up to 20 years.

Abdulyanov A.V., Gribova Y.V., Krasilnikov D.M., Safiullin M.R., Safiullin R.S., Shakirova D.H. 3890

This article presents the results of the ATC/DDD analysis of the use of antibacterial drugs for the treatment of patients with pancreonecrosis in a hospital environment. The publication contains the necessary procedures for conducting research and main research results.

Serpik V.G., Yagudina R.I. 3886

The limited financing of the program of pharmacological support of high-cost nosologies emphasizes the importance of more effective use of the available resources. In order to improve the efficiency of use of the available resources of pharmacological support of inhibitor hemophilia patients receiving therapy in the prophylactic regimen, a budget impact analysis of prophylactic treatment by BPA anti-inhibitor coagulant complex and eptacog alfa [activated] was performed. In accordance with the instructions for use of eptacog alfa, this medicinal product is not indicated for long-term preventive treatment of bleedings, however, as eptacog alfa is used in the said regimen, it was included in the analysis. The analysis horizon period made 1 year and 75 patients were included in the analysis. The analysis shows that prophylactic anti-inhibitor coagulant complex therapy offers better control over the disease and reduces the costs. The incidence of bleedings in prophylactic anti-inhibitor coagulant complex therapy is reduced by 72.5%, while the incidence of bleedings in prophylactic treatment by eptacog alfa is reduced by 59% as compared to on demand therapy. The annual costs of prophylactic anti-inhibitor coagulant complex therapy per patient make 58.8 million rub (per adult patient) and 23.5 million rub (per pediatric patient), while the annual costs of bleeding prophylactic eptacog alfa treatment proved to be higher by 37.4% and made 94 million rub per adult patient and 37.6 million rub for pediatric patient. Transfer of all patients who respond to anti-inhibitor coagulant complex therapy and receive therapy with this medicinal product in prophylaxis regimen will save 765 million rub or 17.3% of the budget, provided that the current distribution of patients is preserved. Thus, the budget impact analysis demonstrates that the transfer of patients receiving therapy with eptacog alfa in prophylaxis regimen to AICC will improve the control over disease and save the budget funds under the 7N Program.